Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

altian pharma, s.a. - aceite de semillas de girasol - aceite de semillas de girasol....750.000 mg / nicotinamida (vitamina b3)....9.525 mg / riboflavina (vitamina b2)....0.875 mg / fosfatidilserina 70% en lecitina de soja....108.000 mg / l-selenito metionina....5.500 mg / Ácido fÓlico....0.250 mg / tiamina monohidrato (vitamina b-1)....0.898 mg / clorhidrato de piridoxina (vitamina b6)....1.550 mg / sulfato de cobre anhidro....1.140 mg / ascorbato cÁlcico....62.920 mg / sulfato de manganeso monohidratado....3.100 mg / coenzima q10....10.000 mg / d-biotina (vitamina b7)....0.018 mg / l-acetil-carnitina hcl....25.000 mg / cianocobalamina (vitamina b12)....1.565 mg / Ácido alfa r-lipoico....25.000 mg / colecalciferol (vitamina d3)....0.003 mg / acetato de dl-alfa tocoferol (vitamina e)....12.850 mg

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - ifosfamide (unii: um20qqm95y) (ifosfamide - unii:um20qqm95y) - ifosfamide 50 mg in 1 ml - ifosfamide injection is indicated for use in combination with certain other approved antineoplastic agentsfor third-line chemotherapy of germ cell testicular cancer. it should be used in combination with mesna for prophylaxis of hemorrhagic cystitis. ifosfamide is contraindicated in patients with: • known hypersensitivity to administration of ifosfamide. • urinary outflow obstruction. ifosfamide can cause fetal harm when administered to a pregnant woman. fetal growth retardation and neonatal anemia have been reported following exposure to ifosfamide-containing chemotherapy regimens during pregnancy. animal studies indicate that ifosfamide is capable of causing gene mutations and chromosomal damage in vivo . in pregnant mice, resorptions increased and anomalies were present at day 19 after a 30 mg/m2 dose of ifosfamide was administered on day 11 of gestation. embryo-lethal effects were observed in rats following the administration of 54 mg/m2 doses of ifosfamide from the 6th through the 15th day of gestation

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - ifosfamide (unii: um20qqm95y) (ifosfamide - unii:um20qqm95y) - ifosfamide 1 g - ifosfamide for injection is indicated for use in combination with certain other approved antineoplastic agents for third-line chemotherapy of germ cell testicular cancer.  it should be used in combination with mesna for prophylaxis of hemorrhagic cystitis.  ifosfamide for injection is contraindicated in patients with: - known hypersensitivity to administration of ifosfamide. - urinary outflow obstruction. pregnancy category d [see warnings and precautions (5.8)] . ifosfamide for injection can cause fetal harm when administered to a pregnant woman.  fetal growth retardation and neonatal anemia have been reported following exposure to ifosfamide-containing chemotherapy regimens during pregnancy. animal studies indicate that ifosfamide is capable of causing gene mutations and chromosomal damage in vivo . in pregnant mice, resorptions increased and anomalies were present at day 19 after a 30 mg/m2 dose of ifosfamide was administered on day 11 of gestation.  embryo-lethal effects were observed in rats following t

United States - English - NLM (National Library of Medicine)

baxter healthcare corporation - ifosfamide (unii: um20qqm95y) (ifosfamide - unii:um20qqm95y) - ifosfamide 1 g in 20 ml - ifosfamide for injection is indicated for use in combination with certain other approved antineoplastic agents for third-line chemotherapy of germ cell testicular cancer. it should be used in combination with mesna for prophylaxis of hemorrhagic cystitis. ifosfamide for injection is contraindicated in patients with: ifosfamide for injection can cause fetal harm when administered to a pregnant woman. fetal growth retardation and neonatal anemia have been reported following exposure to ifosfamide-containing chemotherapy regimens during pregnancy. animal studies indicate that ifosfamide is capable of causing gene mutations and chromosomal damage in vivo . in pregnant mice, resorptions increased and anomalies were present at day 19 after a 30 mg/m2 dose of ifosfamide was administered on day 11 of gestation. embryo-lethal effects were observed in rats following the administration of 54 mg/m2 doses of ifosfamide from the 6th through the 15th day of gestation and embryotoxic effects were apparent after dams rece

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - ifosfamide (unii: um20qqm95y) (ifosfamide - unii:um20qqm95y) - ifosfamide 1 g - ifosfamide for injection, used in combination with certain other approved antineoplastic agents, is indicated for third line chemotherapy of germ cell testicular cancer.  it should ordinarily be used in combination with a prophylactic agent for hemorrhagic cystitis, such as mesna. continued use of ifosfamide for injection is contraindicated in patients with severely depressed bone marrow function (see warnings and precautions sections).  ifosfamide for injection is also contraindicated in patients who have demonstrated a previous hypersensitivity to it.

United States - English - NLM (National Library of Medicine)

mylan institutional llc - ifosfamide (unii: um20qqm95y) (ifosfamide - unii:um20qqm95y) - ifosfamide 50 mg in 1 ml

United States - English - NLM (National Library of Medicine)

pfizer laboratories div pfizer inc. - ifosfamide (unii: um20qqm95y) (ifosfamide - unii:um20qqm95y) - ifosfamide 50 mg in 1 ml

United States - English - NLM (National Library of Medicine)

baxter healthcare corporation - ifosfamide (unii: um20qqm95y) (ifosfamide - unii:um20qqm95y) - ifosfamide for injection is indicated for use in combination with certain other approved antineoplastic agents for third-line chemotherapy of germ cell testicular cancer. it should be used in combination with mesna for prophylaxis of hemorrhagic cystitis. ifosfamide for injection is contraindicated in patients with: ifosfamide for injection can cause fetal harm when administered to a pregnant woman. fetal growth retardation and neonatal anemia have been reported following exposure to ifosfamide‑containing chemotherapy regimens during pregnancy. animal studies indicate that ifosfamide is capable of causing gene mutations and chromosomal damage in vivo . in pregnant mice, resorptions increased and anomalies were present at day 19 after a 30 mg/m2 dose of ifosfamide was administered on day 11 of gestation. embryo-lethal effects were observed in rats following the administration of 54 mg/m2 doses of ifosfamide from the 6th through the 15th day of gestation and embryotoxic effects were apparent after dams rec

Malta - English - Medicines Authority

baxter healthcare limited - ifosfamide - powder for concentrate for solution for infusion - ifosfamide 2 g - antineoplastic agents

Canada - English - Health Canada

fresenius kabi canada ltd - ifosfamide - powder for solution - 1g - ifosfamide 1g - antineoplastic agents